Overview

Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This pilot study will make a preliminary determination of the safety of ustekinumab in patients with Primary Sjogren's Syndrome (PSS) and assess the response of systemic measures of inflammation (biomarkers).
Phase:
Phase 1
Details
Lead Sponsor:
University of Rochester
Treatments:
Ustekinumab